Cure My Disease

Don't miss your cure!

 Log in / Sign up

What drives people to Self-Treat with psychedelics? a study investigates

NCT ID NCT06014164

Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study explores the experiences of people diagnosed with a psychiatric disorder who have used psychedelic substances on their own to relieve symptoms. Researchers will conduct in-depth interviews with 20 participants to understand their motivations, methods, and perceived effects. The goal is to gather real-world insights that could inform future research and clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
psychedelic substances (self-administered)
What this could lead to
This could help researchers design safer, more effective clinical trials of psychedelic therapies for psychiatric conditions.
What could go wrong
This is a small, observational interview study with only 20 participants, so findings may not apply broadly. It does not test any treatment itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

20 people

The number who actually took part.

Started

Nov 2023

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults patients self-administering psychodelic substances for therapeutic purposes

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with a psychiatric disorder by a psychiatrist or general practitioner * Patients used psychedelic or related substances in order to treat psychiatric symptoms * Patients have given their oral non-opposition * Patients affiliated to a social security scheme Exclusion Criteria: * Patients who don't speak or understand French * Patients under protection, guardianship or curators

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psychiatric disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychiatric disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psychiatric disorder

Contacts and locations

Locations

  • University Hospital Toulouse

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.